ERBB2 and breast carcinoma: Ongoing trials, such as NCT03608618 and NCT04660929, are evaluating CAR-Ms that target mesothelin and HER2, respectively, in patients with advanced ovarian cancer, malignant peritoneal mesothelioma, breast cancer, and gastroesophageal cancer.